Search

Tandutinib

MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. … Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration.

Edivoxetine

Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant … Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.

ALS-08

ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

Clofutriben

Clofutriben is a small molecule drug. Clofutriben is under investigation in clinical trial NCT05307328 (SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome). … Clofutriben has a monoisotopic molecular weight of 424.09 Da.

Perospirone

It also displays affinity towards 5HT1A receptors as a partial agonist. … Perospirone is an atypical or second-generation antipsychotic of the azapirone family that antagonizes serotonin 5HT2A receptors and dopamine D2 receptors.

5-Methoxy-N,N-diisopropyltryptamine

Since 1999, there has been a growing popularity of 5-MeO-DIPT among drug abusers. This substance is abused for its hallucinogenic effects. … 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) is a tryptamine derivative and shares many similarities with schedule I tryptamine hallucinogens such as alpha-ethyltryptamine, N,N-dimethyltryptamine,

Betaxolol

A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.

N,N'-diphenyl-1,4-phenylenediamine

Bentonite

Inosine

A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose.